Genetic Engineering & Biotechnology News

SEP15 2017

Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D community with critical information on the tools, technologies, and trends that drive the biotech industry.

Issue link: http://gen.epubxp.com/i/869753

Contents of this Issue

Navigation

Page 30 of 77

Genetic Engineering & Biotechnology News | GENengnews.com | SEPTEMBER 15, 2017 | 29 "However, instead of trying to automate the diagnostic work and lose control of the diagnostic decisions, we should try to build great tools that empower pathologists based on the novel technology. Pathologists should stay in control, because once systems are fully automated, they tend to stop improving with the same pace." For the future, paradigm shifts will likely continue to occur in cancer care and other therapeutics as precision medicine and per- sonalized treatments take stronger hold. Pathologists and their interactions with non- pathology departments are central to this dream of personalized medicine. It is at the desk of the pathologist where first clinical decisions regarding the patient are made. Molin philosophizes, "Technology can to- day not fully replace the requirement for hu- man interactions." Custom Systems BioGenic Contact us today 1.800.523.0072 www.custombiogenics.com/GEN Inventory Systems Long Term Storage & Transport Monitoring Controlled Rate Freezers Custom Systems BioGenic Your Complete Solution Your Complete Solution for freezing and storing cell lines and biologicals Aids in compliance with 21 CFR Part 11 Freeze vials, cryo-bags, cains and more Temperature range from -180°C to +50°C Custom sizes available Benchtop Controlled Rate Freezers High Capacity Controlled Rate Freezers Are you scaling up cell line production? Translational Medicine At-Home Fertility Testing Insights We live in an age of mobile bank- ing, wrist-mounted pedometers, and menstruation-tracking apps. And yet, actual fertility diagnostic information is hard to come by and prohibitively expensive. Afton Vechery and Carly Leahy recently launched Modern Fertil- ity, a company that offers afford- able, easy-to understand, at-home fertility testing. The cofounders' for- mer positions illustrate the aim of this company: Vechery was prod- uct manager at 23andMe, and Leahy was senior creative strategist at Uber Everything. The company aims to empower women by deliv- ering hormone measurements, so they can make informed choices about their fertility at home, rather than having to visit a fertility clinic. The benefits of the test include its price ($149), and its simplicity. The test measures up to 10 hor- mones, depending on the method of birth control the woman is using, and delivers a report that describes the implications of the levels of each hormone. Testing the hormones AMH, FSH, E2, LH, TSH, FT4, P4, PRL, FREE T, and T gives a physician-reviewed report on ovar- ian reserve, ovulation stability, and general body functions as they relate to fertility. Modern Fertility is backed with $1 million from First Round Group, Box Group, Y Combinator, and angel investors. The at-home fertil- ity tests are available for preorder and are slated for delivery later this year. n To enhance its medical diagnostic imaging systems, Sectra is applying artificial intelligence and machine learning technology to help pathologists with time-consuming tasks such as cell counting, allowing pathologists to focus on more advanced tasks. The company also emphasizes integrated diagnostics, which can, for example, facilitate collaboration between radiologists and pathologists by allowing images from both diagnostic specialties to be archived and viewed in a single system.

Articles in this issue

Links on this page

Archives of this issue

view archives of Genetic Engineering & Biotechnology News - SEP15 2017